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Although  the  mucopeptide  ~ of  hemolytic  streptococci  is  not  chemically 
similar  to  the  endoto~n~  of  Gram-negative bacteria,  both  substances  have 
several biological properties in common. For example, streptococcal mucopep- 
tide,  when  injected  into mice,  either  intraperitoneaUy or  intravenously,  en- 
hances the resistance to subsequent challenge with virulent Group A  strepto- 
cocci.  Mucopeptide produces fever in the rabbit  and may initiate  shock and 
death  (1).  A  necrotic skin  lesion  develops in  rabbits  after  local injection of 
mucopeptide (2). In this report, the febrile response after injection of mucopep- 
tide  has  been  studied  in  greater  detail,  and  mucopeptide has  been  used  to 
prepare  and  provoke  the  local  Shwartzman  reaction.  Special  attention  has 
been given to pathologic alterations which occur in the myocardium of rabbits 
after  the  intravenous  administration  of  mucopeptide,  a  finding  which  was 
reported earlier as a preliminary observation (3). 
Materials and Methods 
Streptococcal Strains.--Group A, Type 6 strain S 43/100/14, Group B strain 090 R, and 
Group L strain SHC 16 were used for the preparation of the mucopeptide. The Groups A 
and B strains were obtained from Dr. Rebecca Lancefield, The Rockefeller University, New 
York; the Group L  strain was from the Streptococcus Reference Laboratory, Institute  of 
Epidemiology and  Microbiology, Prague. 
Mucopepti~e and Carbokydrate.--Mucopeptide and  carbohydrate were prepared by ex- 
traction of cell walls with formamide as described by Fuller (4) and modified by Krause and 
McCarty (5). 
Throughout the whole procedure for the preparation of mucopeptide and carbohydrate, 
from the growth of the bacteria to the final lyophifization  of the products, care was taken to 
* The prellmlna~ studies of this work were begun at the time the senior author was a visitiag 
investigator in the laboratory of Dr. Richard M. Krause, Washington University School  of 
Medicine, St. Louis, Missouri, and were supported at that time by United States Public 
Health Service, National Itmtitutes of Health Grant HE 08027, and wore conducted in part 
under the sponsorship of the  Commission on Streptococcal and  Staphylococcal Diseases, 
Armed Forces Epidemiology  Board, and was supported by the Office of the Surgeon General, 
Department of the Army, Wa-qMngton, D.C. 
x Other terms used in the literature for mucopeptide include peptidoglycan and murein. 
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avoid contamination by extraneous pyrogens.  All glassware and containers were heated  to 
180°C for 2 hr; only pyrogen-free water wa~ used to prepare reagents. 
Cell walls were prepared  from streptococci grown for 18 hr in Todd-Hewitt broth.  The 
culture was centrifuged at 4°C and the bacterial sediment was washed three times with dis- 
tilled water  (pyrogen-free water used throughout).  The bacteria were then  resuspended  in 
distilled water in a volume equal to 1/100 of the broth culture volume, and were disrupted in 
a  Mickle disintegrator using Ballotini No.  12  glass beads.  The disintegrated  material was 
TABLE I 
Chemi.al Composition  of Streptococcal Mucopeptide Prepared  from Croup A Strain $43/100/14 
Component  ~anole/mg  t~/mg 
N-Ac-Muramic Acid 
N-Ac-Glucosamine 
Lysine 
Glutamic Acid 
Glycine 
Alanine 
Histidine 
Arginine 
Aspartic Acid 
Threenine 
Serine 
Tyrosine 
Phenylalanine 
Ammonia 
Total Recovery 
0.602 
0.772 
0.822 
0.779 
0.081 
3.145 
0.010 
0.005 
0.014 
0.010 
0.014 
0.024 
0.029 
1.127 
176.55 
170.77 
120.17 
114.63 
6.08 
280.22 
1.55 
0.87 
1.86 
1.19 
1.47 
4.35 
4.79 
19.16 
903.66 
All values are given in terms of the anhydrous ash-free mucopeptide. The lyophil/zed strepto- 
coccal mucopeptide was 6.25% moisture and  2.30% ash.  The #g/rag values for the amino 
sugars have been calculated to include the acetylation of these sugars in the native state. 
The ammonia values were corrected for the amounts of ammonia contributed by decomposi- 
tion of the amino sugars. The amount contributed by degradation of trace amino acids such 
as serine has not been included. 
The authors  are grateful for the assistance of Mr. Henry Lackland, The Rockefeller Uni- 
versity, who performed  these determinations. 
centrifuged  at 6000 rpm (MSE centrifuge,  rotor  no. 9180),  and the sediment was washed 
three times with distilled water. 
Cell walls were treated with ribonuclease and deoxyribonuclease as described by Freimer 
for preparation of protoplast membranes (6), followed by trypsin treatment (5). After dialysis 
against distilled water they were lyophi|ized. The cell walls were extracted twice with hot 
formamide at 180°C to remove the group-specific  carbohydrate from the mucopeptide residue. 
The carbohydrate was recovered from the extract by the described procedure and lyophilized 
(5). The particulate mucopeptide residue was washed extensively with distilled water, dialyzed, 
and lyophilized. 
Cher~ical Analysis of Mucopeptkte.--Glucosamines and amino acids were determined with 
the Beckman amino acid analyzer by the methods of Spackman,  Stein, and  Moore (7),  as 
described by Karakawa et al (8).  Rhamnose was determined by the method of Dische and 
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In any study directed at the biological properties of a substance,  such as  mucopeptide, 
which is obtained in part by cell fractionation procedures,  it is important  to have accurate 
information on the total chemical composition. Special care was taken to avoid the accumu- 
lation of extraneous  material throughout the preparation of the several lots of mucopeptide 
employed here. A typical chemical analysis of a representative batch of mucopeptide  is given 
in Table I..Amino acids and A  rnlno sugars  account  for  88.5%  of  the  material.  Rhamnose 
content was less than 2%. 
Solubilisatios  of Mucopeptide.---One mg of particulate mucopeptide per ml of saline was 
solubilized by ultrasonic treatment in an MSE disintegrator, 20 kc, for 30 rain. Mucopeptide 
solubilized in this fashion was used for the biologic studies and as the antigen in precipitin 
tests for detection of mucopeptide antibodies. 
Antiserum  to Mucopeptkte.--Antisera  were prepared by immunizing rabbits with particu- 
late mucopepfide  isolated from cell walls of Group A, Type 6 streptococcus.  The following 
immunization scheme was used: 1st wk, 2.5 mg mucopeptide in incomplete Freund's adjuvant 
into each foot pad. Each week from the 5th-10th wk, an intraperitoneal injection of 10 mg 
particulate mucopeptide was followed the next day by an intravenous dose of 10 mg muco- 
peptide. 10 days after the last injection, ring and capillary  tests were used to detect antibodies. 
One  of the four immunized  rabbits produced sufficient  antibodies to mucopepfide,  so the 
serum could be used in experimental procedures. 
Endotoxin.--A Difco product prepared from Esckerichia coli 0127:B8 was used. 
E. coli Lipopolysacckaride.--Lipopolysaccharide,  prepared from E. coli 12408 strain, was 
kindly supplied by Dr. E. Work, Twyford Laboratories, Ltd., London. 
Cortisone.--The  cortlsone-acetate is a product of Continental Pharma, Brussels. 
Rabb/ts.--White rabbits weighing 1.7-1.9 kg, kept at a constant temperature and fed on 
standard diet without antibiotic additive, were used for all aspects of these studies. 
Determination of Febrile Response in Rabbits.--Rabbits were employed which had a rectal 
temperature variation less than 0.3°C during 6 hr of observation on the day preceding  the 
experiment.  The material to be tested was injected into the marginal ear vein, and the tem- 
perature was measured from the rectum. 
Unless stated otherwise in the protocols which follow, all preparations examined for pyro- 
genic properties were tested in at least 3 rabbits. Average values were used to plot the fever- 
response curves. 
RESULTS 
Pyrogenic  Properties  of M~opepti~.--In  previous experiments, particulate 
mucopeptide,  recovered as  an  insoluble residue  after  extraction  of cell walls 
with hot formamide, was solubilized by ultrasonic treatment and administered 
intravenously to produce fever in rabbits (1). The dose fever-response curves 
after injection of solubilized mucopeptide are now presented in detail. 
Mucopeptide, after treatment for 30 rain in an MSC ultrasonic disintegrator, 
is referred to as soluble mucopeptide, although this material is heterogeneous 
with respect to size. For example, 49 %  of the disrupted mucopeptide is sedi- 
mented  at 25,000  RCF  (relative centrifugal force) for  1 hr,  and 62%  is sedi- 
mented at 100,000 RCF. 
The  temperature  elevations after injection of soluble mucopeptide are de- 
picted in Fig. la. A  reproducible febrile response which persisted for 12-24 hr 
was obtained with 3.2 #g. When less than this dose was employed, the fever was 
not only lower, but often delayed for 3-5 hr after the injection. Mucopeptide, 34  CELL  WALL  MUCOPEPTIDE  OF  HEMOLYTIC  STREPTOCOCCI 
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FIo.  1¢.  Febrile responses after  intravenous injections of  different doses of  solubflized 
mucopeptide. 
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FIO.  lb.  Febrile responses  after  intravenous injections of  different doses  of particulate 
mucopepfide. Each dose was injected into 3 rabbits. Each curve was obtained by averaging 
the temperature values of three rabbits. JIi~I R01~rA AND BLAIIOSLAV BEDN~I~  35 
which has not been subjected to ultrasonic treatment is  particulate in nature 
and is readily sedimented at 5000 RCF for 30 min. It is much less effective in 
producing  fever.  Dose-fever  response  curves  after  injection  of  particulate 
mucopeptide are depicted in Fig.  lb.  80 #g of particulate mucopeptide was 
required to produce a fever response comparable to that achieved with 3.2 #g 
of sonically disrupted mucopeptide. 
Studies to determine optimal particle size of the sonically disrupted mucopep- 
tide for the production of fever were inconclusive. It was clear, however, that 
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FzG. 2.  Febrile responses after intravenous injections of different doses of Groups B and L 
solubilized  mucopeptide. Each dose was injected into 3 rabbits. Each febrile response curve 
is the average for 3 rabbits. 
fever was produced by mucopeptide particles which were not sedimented at 
either 25,000 RCF or 100,000 RCF for 1 hr. 
A  large  body of  information suggests  that  the  mucopeptides  of  several 
different serologic  groups of hemolytic streptococci are similar chemical com- 
pounds (5,  8).  It was anticipated, therefore, that the mucopeptides of these 
other  groups  would  also  have  pyrogenic  activity.  The  dose-fever  response 
curves for Groups B  and L  solubilized mucopeptides are presented in Fig. 2. 
10 #g elicited a reproducible febrile response, although injection of as little as 
1 #g was sufficient to produce detectable fever. 
The febrile response to mucopeptide, like that to endotoxin, can be readily 
diminished or eliminated by pretreatment with cortisone.  Four rabbits  were 
given 10 mgm of cortisone intramuscularly twice a  day for 2 days. Mter the 
last dose, 2 mg of soluble mucopeptide was injected intravenously. During the 
subsequent 10 hr, no fever was noted while control rabbits  responded in the 
usual fashion. 35  CELL  WALL MUCOPEPTIDE  OF  HEMOLYTIC STREPTOCOCCI 
One  interpretation  of  the  febrile response  after injection of streptococcal 
mucopeptide is  that  it may have become contaminated with  an  extraneous 
pyrogen during preparation. Against this possibility is the fact that the group- 
specific carbohydrate, isolated from the same cell wall extract which served as 
the  source of mucopeptide, is neither pyrogenic nor toxic. For example,  the 
temperature of rabbits remained within 0.2°C of control levels after intravenous 
injection of 2.0 mgm of Group A carbohydrate. The possibility that the muco- 
peptide is toxic because of an extraneous substance also appears unlikely as a 
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FIG. 3.  Neutralization of the pyrogenic activity of solubilized  mucopeptide by antiserum 
to mucopeptide. See text for description of materials injected. Each febrile response curve is 
the average for 3  rabbits. 
result of additional  experiments which have made use of mucopeptide anti- 
serum.  The  addition  of  antiserum  to  solubilized  mucopeptide  eliminated 
pyrogenic activity. 
Optimal  proportions  of  mucopeptide  and  antiserum  were  determined  by 
prior precipitin reactions.  To each 0.9 ml  of antiserum to mucopeptide was 
added 0.1  ml of saline  containing 50 ~g of solubilized mucopeptide and  the 
mixture incubated for 1 hr at 20°C  and then for 18 hr at 4°C.  The immune 
precipitate was centrifuged at 2000 rpm for 30 min and the pyrogenic activity 
of the supernatant fluid was tested in rabbits. Each rabbit received 1.0 ml of 
this  supernatant.  Control  rabbits  received  an  equal  volume of  supernatant ROTTA AND BLAHOSLAV BEDN~  37 
fluids of the following mixtures which were prepared according to the following 
proportions: 0.9 ml of normal rabbit serum and 0.1 ml of solubillzed mucopep- 
tide; 0.9 ml of saline and 0.1 ml of mucopeptide; and 0.9 ml of antiserum and 
0.1 ml of saline. The pyrogenic responses of the rabbits injected with each of the 
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FIG,  4.  Induction of tolerance with  16 daily intravenous  injections of 0.5  /~g of E.  coli 
lipopolysaccharide. 
Upper frame. The febrile response  curves represent the average temperatures for 3 rabbits 
on day 1 and day 16 after the attmlnlgtration of the daily dose of endotoxin. 50/zg of solu- 
bilized mucopeptide was injected intravenously on the 17th day. 
Lower frame. Similar  febrile response  curves for the average of 3 other rabbits after injec- 
tions of endotoxin. In this case 20 ~tg of solubilized mucopeptide  was injected intravenously 
on the 17th  day. 
supernatant fluids are recorded in Fig. 3. The supernatant fluid from the muco- 
peptide-antimucopeptide mixture did  not  produce fever, whereas  the  super- 
natant fluids of mucopeptide alone, and normal rabbit serum and mucopeptide 
produced a predictable and typical febrile response for this dose of mucopeptide. 
Similar results were obtained when the same antiserum prepared with Group A 
mucopeptide was used in conjunction with Group B mucopeptide. These results 
indicate that the pyrogenic dement in solubilized mucopeptide is precipitated 
by mucopeptide antiserum, and argue against the possibility that the pyrogenic 38  CELL  WALL  MUCOPEPTIDE  O~  HEMOLYTIC  STREPTOCOCCI 
property of mucopeptide is the result of contamination with ubiquitous pyro- 
gens. 
An extensively studied aspect of the fever induced in rabbits by endotoxin is 
the tolerance which develops with repeated injections (10). Because endotoxins 
of Gram-negative bacteria and streptococcal mucopeptide are chemically quite 
different substances, it was anticipated that rabbits which were made tolerant 
to endotoxin of  Gram-negative bacteria would  nevertheless respond  to sub- 
sequent injection of streptococcal mucopeptide. Rabbits were made tolerant to 
the lipopolysaccharide of E. coli by daily injections of 0.5/~g for 16 days. The 
TABLE II 
Local Shwartzman Reactions  Obtained with Solubili~ed Mucopeptide  and E. coli Endotoxin 
No. of 
Intradermal injection  Intravenous injection  No. of  rabbits  rabbits  with 
reaction 
mg  mg 
Streptococcal mucopeptide  Streptococcal  mucopeptide 
0.4  0.4  3  1 
0.4  2.0  2  1 
2.0  0.4  3  1 
2.0  2.0  3  2 
Streptococcal  mucopeptide  E. coli endotoxin 
0.4  0.1  3  1 
2.0  0.1  3  1 
E. coli endotoxin  Streptococcal  mucopeptide 
0.1  0.4  3  2 
0.1  2.0  5  5 
The interval between the intradermal and intravenous injections was 24 hr. The mucopeptide 
had been solubilized  by ultrasonic treatment. Difco E. coli endotoxin  was used. 
following day they were challenged with  solubilized mucopeptide.  A  control 
group of rabbits were injected daily for 16 days with saline and on the following 
day challenged with mucopeptide. The results are presented in Fig. 4. Although 
20 #g of mucopeptide did not break the  tolerance of the  endotoxin-tolerant 
rabbits, 50/~g of mucopeptide was sufficient to do so. Either the 20/~g or the 
50/~g dose of mncopeptide elicited a prompt, brisk febrile response in control 
rabbits. An attempt was made to do the reciprocal experiments in which endo- 
toxin was  given to break tolerance produced with mucopeptide.  The results 
were  inconclusive,  however,  because  tolerance  after  repeated  injections  of 
mucopeptide was inconstant. 
The  Local  Skwartzman  Phenomenon.--One  of the most  thoroughly studied 
biological properties of endotoxin is the capacity to prepare and provoke the 
general and local Shwartzman phenomena (11).  Because there is a resemblance JI~l ROTTA AND BLAHOSLAV  BEDN~I~  39 
between  the biological properties  of mucopeptide thus far described and those 
of endotoxin of Gram-negative  bacteria, attempts were made also to produce 
the Shwartzman phenomenon with mucopeptide.  Two intravenous injections 
of mucopeptide,  spaced 24 hr apart, failed to produce the generalized Shwartz- 
man phenomenon.  Various dosage schedules from 0.4-10  mg were employed 
for both the preparatory and the provocative injections.  Autopsy search  of 
rabbits revealed  no evidence of bilateral cortical  necrosis of the kidney. For 
reasons which remain unexplained,  2 of the 12 rabbits tested died a few rain 
after the provocative dose of mucopeptide. 
Success was achieved when mucopeptide  was used to prepare  and provoke 
the localized Shwartzman phenomenon. The injection schedule, the number of 
rabbits employed, and the number of rabbits which exhibited a localized reac- 
tion are presented in Table II. Endotoxin could be substituted for mucopeptide 
as the preparative injection,  as well as the provocative  injection.  A picture of 
the localized Shwartzman reaction is presented in Fig. 5. In additional studies, 
intravenous injection of either Group B or Group L  solubillzed mucopeptide 
was used to provoke  the localized Shwartzman reaction in rabbits prepared 
with an intradermal injection of E. coti endotoxin. 
Intravenous injections  of particulate mucopeptide  did not provoke  a  local 
reaction in rabbits which  had received  intravenous injections  of endotoxin. 
Group A carbohydrate, isolated from the same formamide extract as the muco- 
peptide,  was ineffective in eliciting the Shwartzman phenomenon. 
Other Toxic Effects  of Mucopeptide.--Because  of the death of some of the 
rabbits after intravenous administration of mucopeptide, histologic studies were 
undertaken to determine possible pathologic alterations. 
Rabbits were injected intravenously with 2 mg, 80 ~g, and 1 gg of solubilized 
mucopeptide.  Each  dose  of mucopeptide  was  injected into  5  rabbits.  Five 
control rabbits were injected with saline which had been exposed in a control 
fashion to the sonic oscillator. Rabbits were killed by decapitation 48 hr after 
injection.  Gross inspection revealed no significant alteration of the organs. 
Although histologic examination of the fiver, spleen, and skeletal muscle re- 
vealed minimal nonspecitic changes, extensive alterations were observed in the 
heart. While the extent of these changes depended upon the size of the dose of 
mucopeptide,  the character of the pathology in each instance was the same. 
Three of five rabbits injected intravenously  with 2 mg of solubilized mucopep- 
tide had the extensive pathologic  alterations in the right ventricle which are 
depicted in Fig. 6, a, b, c. There is intense myocardial degeneration  obviously 
involving the cardiac muscle cells. Various stages of degeneration  and necrosis 
are observed. Extrusion of nuclei has occurred. Occasional nuclei of the cardiac 
cells are in metaphase, suggesting initiation of regeneration.  These alterations 
are not seen in the smooth muscle of the coronary vessels. There is a striking 
infiltration of polymorphonuclear  leukocytes  into the tissue.  Although these 40  CELL  WALL  MUCOPEPTIDE  O]~  HEMOLYTIC  STREPTOCOCCI 
alterations are  most extensive  in the  fight  ventfide,  changes  are  observed 
elsewhere in the myocardium also. Similar changes, but somewhat less marked, 
were seen in the hearts of the other two rabbits injected with 2 mg of solubilized 
mucopeptide. 
Three of the five rabbits injected with 80/zg of mucopeptide and three d  the 
five rabbits injected with i  #g of mucopeptide  had a carditis  similar  to that 
described above, but the extent was proportionately less. For example, in the 
case of rabbits which were injected with 1/zg of solubilized mucopeptide,  these 
alterations were observed approximately  once in every 10 microscopic fields at 
X350  magnification.  There were no changes in the hearts of the five rabbits 
injected with saline. 
Microscopic examination of five rabbits injected with particulate mucopep- 
tide revealed minimal pathologic alterations in the heart. It is conceivable that 
the particulate material is cleared by passage through the pulmonary-capillary 
bed and does not reach the myocardium. Additional rabbits were tested to gain 
some information on the particle size of the material which produced the lesions. 
One mg/ml was solubilized by ultrasonic treatment and aliquots centrifuged at 
25,000 RCF and 100,000 RCF for I hr. Rabbits were injected with 1 ml of the 
supernatants of each aliquot. The extent and severity of the lesions were similar 
to those observed in rabbits injected with solubilized mucopeptide  which had 
not been centrifuged. 
In another series of experiments rabbits were examined up to 10 days after 
injection of mucopeptide.  Six rabbits were injected with 100/~g, and six with 
10 gg of solubilized mucopeptide.  Three rabbits from each dosage group were 
autopsied at 3 days and 10 days. The microscopic findings in the hearts at 10 
days were similar to those observed at 3 days. Control rabbits revealed negative 
findings. Lesions were not observed in skeletal muscle. 
The basis  for  these  pathologic  alterations in  the  heart  after intravenous 
injection of mucopeptide  remains unexplained.  In studies currently underway, 
mucopeptide  did not possess direct toxicity for the isolated  perfused  rabbit 
heart? 
DISCUSSION 
The biological properties  of streptococcal  mucopeptide  described  in detail 
here  augment the  current information on  its  chemical  nature.  The  general 
outline for the structure of bacterial mucopepfides has been now largely clarified 
(12, 13, 14). These substances consist of repeating units of N-acetyl glucosamine 
and N-acetyl-muramic acid. In the case of streptococcal mucopeptide, tetrapep- 
tides composed of L-alanine, D-glutamic acid, glycine, and D-alanlne are linked 
to the hexosamine polymer through the carboxyl group of the muramic acid, 
and in turn, the tetrapepfides of adjacent hexosamine polymers are covalently 
Ra~kov~, H., K. Ma~ek, and J. Rotta. Personal  communication. ROTTA  AND  BLAHOSLAV  BEDN~/~  41 
cross-linked by L-alanyl-L-alanine to form a matrix (15).  The mucopeptides of 
the various bacteria differ primarily in  the  amino acid content  of the  tetra- 
peptides  and  the  cross-link  peptides.  The  mucopeptides  of  certain  Gram- 
negative  organisms,  for  example,  contain  diaminopimelic  acid  instead  of 
lysine in the tetrapeptide,  and  the  cross-links  of  staphylococci  are  peptides 
of glycine  (12).  Thus,  it is clear that the mucopeptides are chemically unlike 
the  endotoxins  of  Gram-negative  bacteria.  Although  it  is  known  that  the 
endotoxins  consist  of  the  lipopolysaccharide  moiety  of  the  somatic  O  an- 
tigen,  there is much which is  as  yet  uncertain  about  the  chemical  structure 
(16). 
A number of the special biological and toxic properties of the Gram-negative 
endotoxins have now been described for streptococcal mucopeptide. The febrile 
response in rabbits after 'intravenous injection of mucopeptide has been pre- 
sented in detail here. Intraperitoneal or intravenous administration of strepto- 
coccal mucopeptide in mice enhances resistance to subsequent challenge with 
virulent  Group A  streptococci  (1).  Abdulla  and  Schwab have shown  dermal 
necrosis after intradermal injection of streptococcal mucopeptide into the skin 
of rabbits (2). Finally, in the studies reported here, streptococcal mucopeptide 
was  successfully employed to prepare  and  to provoke the local  Shwartzman 
phenomenon. 
These properties of streptococcal mucopeptide differ to some extent from those of 
a streptococcal endotoxin described by Stetson (17). This latter material was obtained 
from the supernatant fluid of disrupted  Group A streptococci which had been cen- 
trifuged to remove the cell walls. While the chemical nature of Stetson's streptococcal 
endotoxin is not known,  it is unlikely on the basis of the method of preparation that 
it was derived from cell walls, or that it is identical with the mucopeptide described 
here. Furthermore, the two products appear to have some differences in their biologic 
effects. The streptococcal endotoxic material prepared by Stetson induced a state of 
tolerance to the pyrogenic effect which could be broken with subsequent Gram-nega- 
tive endotoxin,  while the induced tolerance achieved with streptococcal mucopeptide 
was inconstant. The local Shwartzman reaction appears in about 3 hr after the intra- 
venous injection of the streptococcal endotoxin which is also the case for the Gram- 
negative endotoxins.  In contrast,  skin  hemorrhage and necrosis  appear in approxi- 
mately 30 min after intravenous injection of mucopeptide. Such an accelerated reac- 
tion has also been reported after intravenous injection of nonspecific materials, such 
as starch and agar (11), into rabbits with suitable prepared skin sites. 
It has yet to be learned if the toxic properties of mucopeptide are due to intrinsic 
toxicity of the substance or due to hypersensitivity or immunity. Such  a  dilemma 
persists in regard to Gram-negative bacterial endotoxin.  Stetson has argued that the 
endotoxins possess biologic activity only by virtue of their antigenidty and that the 
toxic properties are not manifestations of an intrinsic tox~dty but a reflection  of an 
immune or a hypersensitivity response.  Such an argument, supported by the findings 
of a  number of investigators, has been summarized recently (18).  Needless  to say, 
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that piglets,  obtained by hysterectomy and  deprived of  colostrum,  possessed  no 
immunoglobulins,  but were nevertheless  sensitive  to the lethal effects of endotoxin 
(19). Such data argue in favor of an intrinsic toxic property of endotoxin which is not 
dependent upon acquired immunity. 
These comments on the role of immunity in the toxicity of endotoxin may be rele- 
vant to a  consideration  of the  toxicity of mucopeptide.  Cromartie,  Schwab,  and 
Ohanian have suggested that the toxic properties of cell walls are due to thepersistence 
of fragments as durable material in the tissue, thus leading to focal lesions. It is argued 
that the mucopeptide is the toxic moiety of the cell wall fragments (20, 21). On the 
other hand, there is now accumulating  evidence that the mucopeptides are antigenic 
and that immune sera produced by injection of bacterial vaccines contain mucopep- 
tide antibodies  (8, 22-26). Immunochemicai  data suggest that such antisera contain 
antibodies  to the peptide moiety and antibodies to the hexosamine polymer of the mu- 
copeptide (22). Furthermore, immunologic cross-reactivity among the mucopeptides 
of several different Gram-positive  bacteria,  including  staphylococci  and  hemolytic 
streptococci,  has been observed. The immunochemical basis for this cross-reactivity 
is due to the fact that the mucopeptides  of these  two organisms  contain chemically 
similar  tetrapeptides  (8).  It  is  reasonable  to presume that additional  studies  will 
reveal widespread  immunologic  cross-reactivity among the bacterial  mucopeptides. 
Thus, prolonged and continuous exposure of animals  and  man to bacteria provides 
a means for the natural acquisition  of sensitivity to these  substances.  It remains to 
be determined if any  of  the  toxic reactions  are  either  diminished  or  eliminated 
when mucopeptide is injected into germfree animals. Such an outcome would suggest 
that  the pathogenesis  of the  toxic manifestations  depends  in part upon acquired 
immunity. 
In the studies reported here, an extensive carditis, more pronounced in the 
right ventricle, was the most dramatic toxic effect after intravenous administra- 
tion of streptococcal mucopeptide into rabbits.  2  and 3  days after injection, 
necrosis  of  myocardial  cells  and  infiltration with  leukocytes  was  observed. 
Examination of rabbits  10 days after injection revealed a  persistence of this 
carditis. These findings in the heart are similar in some respects to those seen in 
the  myocardium  of  mice  after  intravenous  or  intraperitoneal  injection  of 
sonically  disrupted  Group  A  streptococci  or  sonicaily  disrupted  Group  A 
streptococcal cell walls (21,  27). It is suggested by these authors that in this 
case, also,  the mucopeptide is the toxic moiety of the cell wall fragments, but 
the proof is indirect, because cell walls,  and not mucopeptide alone were in- 
jected. Nevertheless, the evidence obtained by immunofluorescent techniques 
is convincing that cell wail fragments persist for prolonged periods in the heart 
after injection of the material into the peritoneum (21). 
There does appear to be a major difference between the dose of mucopeptide 
required to produce cardiac lesions as described here for rabbits and the dose of 
cell wall fragments required to produce cardiac lesions in mice (27). 80 #g of 
sonicaily disrupted mucopeptide was su/ficient to produce carditis in rabbits, Jli~I ROTTA AND BLAHOSLAV BEDN~Li~  43 
whereas the sonically disrupted Group A streptococci which was injected intra- 
venously into mice contained at least 200-400 ~g of cell walls (27).  These dif- 
ferences in dosage which  are required  to produce  the cardiac lesions may be 
due to the quite different nature of the materials employed, or reflect variability 
between the two species. The relationship of this mucopeptide-induced carditis 
to the other toxic manifestations of mucopeptide remains to be determined. 
Note added  to proof:  The authors have been informed by Dr. W.  W.  Karakawa 
and  Dr.  P.  Maurer  that  tanned  red  ceils undergo lysis upon exposure to strepto- 
coccal mucopeptide. Dr. M. R~,e, Dr. H. Ra~kovh,  and Dr. J. Rotta have recently 
found  that thrombocytes are lysed by mucopeptide. It is conceivable  that the toxic 
manifestations of mucopeptide described  here may be related to this lytic property. 
SUMMARY 
Several of the toxic properties of streptococcal mucopeptide have been studied 
in detail.  Intravenous injection of as little as 1 #g of mucopeptide, solubilized 
by ultrasonic treatment,  elicits a reproducible febrile response. Rabbits which 
are made tolerant to Escherichia coli endotoxin are only partially tolerant to the 
subsequent  injection  of streptococcal mucopeptide.  Soluble mucopeptide was 
successfully  employed  to  prepare  and  provoke  the  localized  Shwartzman 
reaction. 
Intravenous injection  of 80/zg  of solubilized  mucopeptide leads  to  diffuse 
cellular infiltration as well as focal areas of myocardial necrosis, surrounded by 
inflammatory cells. 
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FIG. 5.  The localized  Schwartzman reaction provoked by an intravenous injection 
of 2 mg of solubilized mucopeptide into a rabbit pretreated 24 hr earlier with an intra- 
dermal injection of  100 ~g of E.  coli endotoxin. Endotoxin injected into the skin at 
the right; saline injected to the left. FIG. 6. a, b, c.  Representative microscopic sections of  the  right  ventricle of  the 
heart of a rabbit 2 days after the intravenous injection of 2 mg of solubilized muco- 
peptide. Hematoxylin and eosin stain X  250. Myocardial cells are in various stages 
of degeneration and necrosis.  A  number of po|ymorphonuclear leukocytes have mi- 
grated into the tissue. 
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